Safety issues surrounding the use of aromatase inhibitors in breast cancer

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.2, Iss.1, 2003-01, pp. : 73-86

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aromatase inhibitors and breast cancer prevention

By Litton Jennifer Keating Arun Banu K Brown Powel H Hortobagyi Gabriel N

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 3, 2012-02 ,pp. : 325-331

Informa Healthcare

Access to resources Recommend Favorite

Putting the Cardiovascular Safety of Aromatase Inhibitors in Patients with Early Breast Cancer into Perspective: A Systematic Review of the Literature

By Younus Muhammad

Drug Safety, Vol. 34, Iss. 12, 2011-12 ,pp. : 1125-1149

Adis International

Access to resources Recommend Favorite

Aromatase Inhibitors and Inactivators for Breast Cancer Therapy

By Lønning P.E.

Drugs & Aging, Vol. 19, Iss. 4, 2002-04 ,pp. : 277-298

Adis International

Access to resources Recommend Favorite

Aromatase Inhibitors in the Treatment of Postmenopausal Breast Cancer

By Bajetta E.

Drugs & Aging, Vol. 15, Iss. 4, 1999-10 ,pp. : 271-283

Adis International

Access to resources Recommend Favorite

Aromatase inhibitors for breast cancer: pharmacoeconomic considerations

By Higa Gerald M

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 6, 2001-06 ,pp. : 987-995

Informa Healthcare

Access to resources Recommend Favorite